NYSEAMERICAN:NNVC NanoViricides Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.89 +0.01 (+0.53%) (As of 07/1/2022 03:24 PM ET) Add Compare Share Today's Range$1.85▼$1.8950-Day Range N/A52-Week Range$1.04▼$7.86Volume107 shsAverage Volume59,654 shsMarket Capitalization$21.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NanoViricides MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.43 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for NanoViricides. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.22% of the float of NanoViricides has been sold short.Short Interest Ratio / Days to CoverNanoViricides has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in NanoViricides has recently decreased by 18.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNanoViricides does not currently pay a dividend.Dividend GrowthNanoViricides does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NNVC. Previous Next 1.5 News and Social Media Coverage News SentimentNanoViricides has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NanoViricides this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NNVC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NanoViricides insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of NanoViricides is held by insiders.Percentage Held by InstitutionsOnly 8.29% of the stock of NanoViricides is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NanoViricides is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NanoViricides is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanoViricides has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address About NanoViricides (NYSEAMERICAN:NNVC) StockNanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.Read More NNVC Stock News HeadlinesJune 23, 2022 | businesswire.comGenital Herpes Drugs Development Research Report 2022: Descriptive Licensing and Collaboration Details, R&D Brief, MoA & Developmental Activities - ResearchAndMarkets.com - Business WireMay 26, 2022 | rttnews.comPre-market Movers: NTNX, WKME, SNOW, ISPC, NNVC… - RTTNewsMay 25, 2022 | benzinga.comNanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentiall - BenzingaMay 23, 2022 | benzinga.comMid-Morning Market Update: Markets Mixed; Broadcom In Talks To Buy VMWare - Benzinga - BenzingaMay 23, 2022 | seekingalpha.comGeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers' pack - Seeking AlphaMay 23, 2022 | uk.investing.com66 Biggest Movers From Friday By Benzinga - Investing.com UKMay 23, 2022 | benzinga.com24 Stocks Moving in Monday’s Pre-Market Session - Benzinga - BenzingaMay 22, 2022 | uk.investing.comThe Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More By Benzinga - Investing.com UKMay 20, 2022 | uk.investing.com71 Biggest Movers From Yesterday By Benzinga - Investing.com UKMay 19, 2022 | businesswire.comViral Conjunctivitis Drugs in Development Pipeline Guide 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com - Business WireMay 19, 2022 | streetinsider.comNanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application - StreetInsider.comMay 19, 2022 | benzinga.comViral Conjunctivitis Drugs in Development Pipeline Guide 2022, by Stages, Target, MoA, RoA, Molecule Type - BenzingaMay 17, 2022 | benzinga.comNanoViricides Reports that It Has Begun Drug Development To Combat Recent Cases Of Severe Pediatric Hepat - BenzingaMay 17, 2022 | finance.yahoo.comNanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials ApplicationMay 16, 2022 | uk.investing.comNanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis By Benzinga - Investing.com UKMay 16, 2022 | finance.yahoo.comNanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric HepatitisMay 16, 2022 | finance.yahoo.comNanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric HepatitisMay 9, 2022 | seekingalpha.comBetter Therapeutics, Great Elm top healthcare gainers; TherapeuticsMD, Sutro among losers - Seeking AlphaApril 25, 2022 | finance.yahoo.comNanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program - Yahoo FinanceApril 25, 2022 | marketwatch.comNanoViricides Nears Completion of Medicinal Product DossierApril 14, 2022 | benzinga.comBenzinga Elon Musk's Hostile Bid To Take Over TWTR - Daily Stocks To Watch April 14, 2022 Podcast - BenzingaMarch 3, 2022 | finance.yahoo.comNanomedicine Global Market Report 2022 - Yahoo FinanceFebruary 23, 2022 | finance.yahoo.comNanomaterials Global Market Report 2022 - Yahoo FinanceFebruary 15, 2022 | benzinga.comNanoViricides Files Quarterly Report For Period Ending December 31, 2021; Says Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready - BenzingaFebruary 15, 2022 | finance.yahoo.comNanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready - Yahoo FinanceSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:NNVC Previous SymbolNYSEMKT:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees17Year FoundedN/ACompany Calendar Last Earnings5/17/2022Today7/05/2022Fiscal Year End6/30/2023Profitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.97% Return on Assets-30.34% Debt Debt-to-Equity RatioN/A Current Ratio22.89 Quick Ratio22.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.73Miscellaneous Outstanding Shares11,554,000Free Float11,041,000Market Cap$21.84 million OptionableOptionable Beta0.58 NanoViricides Frequently Asked Questions Are investors shorting NanoViricides? NanoViricides saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 353,000 shares, a decline of 19.0% from the May 31st total of 435,700 shares. Based on an average daily volume of 67,300 shares, the short-interest ratio is presently 5.2 days. Currently, 3.2% of the shares of the company are short sold. View NanoViricides' Short Interest. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSEAMERICAN:NNVC) issued its earnings results on Tuesday, May, 17th. The company reported ($0.16) earnings per share for the quarter. View NanoViricides' earnings history. When did NanoViricides' stock split? How did NanoViricides' stock split work? NanoViricides shares reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split. Who are NanoViricides' key executives? NanoViricides' management team includes the following people: Dr. Anil R. Diwan Ph.D., Exec. Chairman, Pres, CEO & Sec. (Age 63, Pay $400k)Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA, Chief Financial Officer (Age 63, Pay $129.6k)Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 75) Who are some of NanoViricides' key competitors? Some companies that are related to NanoViricides include Adagene (ADAG), Cue Biopharma (CUE), Fortress Biotech (FBIO), Ardelyx (ARDX), Hookipa Pharma (HOOK), Enlivex Therapeutics (ENLV), Pyxis Oncology (PYXS), Xilio Therapeutics (XLO), Alzamend Neuro (ALZN), Vicapsys Life Sciences (VICP), Merrimack Pharmaceuticals (MACK), Galectin Therapeutics (GALT), MEI Pharma (MEIP), Magenta Therapeutics (MGTA) and HCW Biologics (HCWB). View all of NNVC's competitors. What other stocks do shareholders of NanoViricides own? Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Inovio Pharmaceuticals (INO), Micron Technology (MU), Gilead Sciences (GILD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), iBio (IBIO) and Moderna (MRNA). What is NanoViricides' stock symbol? NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC." How do I buy shares of NanoViricides? Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NanoViricides' stock price today? One share of NNVC stock can currently be purchased for approximately $1.89. How much money does NanoViricides make? NanoViricides (NYSEAMERICAN:NNVC) has a market capitalization of $21.84 million. The company earns $-8,820,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. How many employees does NanoViricides have? NanoViricides employs 17 workers across the globe. How can I contact NanoViricides? NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The official website for NanoViricides is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at info@nanoviricides.com, or via fax at 203-859-5095. This page (NYSEAMERICAN:NNVC) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
